Limits...
Insulin glargine and cancer risk in patients with diabetes: a meta-analysis.

Tang X, Yang L, He Z, Liu J - PLoS ONE (2012)

Bottom Line: Insulin glargine use was associated with a lower odds of cancer compared with non-glargine insulin use (OR 0.81, 95% CI 0.68 to 0.98, P = 0.03; very low-quality evidence).Glargine did not increase the odds of breast cancer (OR 0.99, 95% CI 0.68 to 1.46, P = 0.966; very low-quality evidence).Compared with non-glargine insulin, no significant association was found between insulin glargine and prostate cancer, pancreatic cancer and respiratory tract cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Endocrinology, the First Hospital of Lanzhou University, Lanzhou, Gansu, China. xulei_tang@126.com

ABSTRACT

Aim: The role of insulin glargine as a risk factor for cancer is controversial in human studies. The aim of this meta-analysis was to evaluate the relationship between insulin glargine and cancer incidence.

Methods: All observational studies and randomized controlled trials evaluating the relationship of insulin glargine and cancer risk were identified in PubMed, Embase, Web of Science, Cochrane Library and the Chinese Biomedical Medical Literature Database, through March 2012. Odds ratios (ORs) with corresponding 95% confidence interval (CI) were calculated with a random-effects model. Confidence in the estimates of the obtained effects (quality of evidence) was assessed by using the Grading of Recommendations Assessment, Development, and Evaluation approach.

Results: A total of 11 studies including 448,928 study subjects and 19,128 cancer patients were finally identified for the meta-analysis. Insulin glargine use was associated with a lower odds of cancer compared with non-glargine insulin use (OR 0.81, 95% CI 0.68 to 0.98, P = 0.03; very low-quality evidence). Glargine did not increase the odds of breast cancer (OR 0.99, 95% CI 0.68 to 1.46, P = 0.966; very low-quality evidence). Compared with non-glargine insulin, no significant association was found between insulin glargine and prostate cancer, pancreatic cancer and respiratory tract cancer. Insulin glargine use was associated with lower odds of other site-specific cancer.

Conclusions: Results from the meta-analysis don't support the link between insulin glargine and an increased risk of cancer and the confidence in the estimates of the effects is very low. Further studies are needed to examine the relation between insulin glargine and cancer risk, especially breast cancer.

Show MeSH

Related in: MedlinePlus

Forest plot evaluating the relationship between insulin glargine and breast cancer incidence.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3526637&req=5

pone-0051814-g003: Forest plot evaluating the relationship between insulin glargine and breast cancer incidence.

Mentions: Eight studies [7], [23], [24], [26]–[29], [31] including 284, 402 study subjects and 1, 364 breast cancer patients reported the of breast cancer in insulin glargine users. The overall OR for the eight studies was 0.99 (95% CI 0.68 to 1.46, P = 0.966; very low-quality evidence) in a random-effects model for insulin glargine versus non-glargine insulin. A significant heterogeneity was detected (P = 0.000, I2 = 79.9%, Table 2 and Figure 3). In stratified analyses by study design [7], [23], [24], [26]–[29], the odds of breast cancer was not elevated with insulin glargine use compared to non-glargine insulin use in observational studies (OR 1.02, 95% CI 0.68 to 1.53, P = 0.92; p for heterogeneity = 0.000, I2 = 83%). After removing two studies by Morden et al.[27], and Colhoun et al.[7] in which not all patients were free of a history of any cancer before cohort entry, the overall outcome remained the same (OR 0.77, 95% CI 0.49 to 1.21, P = 0.26), with significant heterogeneity (P = 0.002, I2 = 73%).


Insulin glargine and cancer risk in patients with diabetes: a meta-analysis.

Tang X, Yang L, He Z, Liu J - PLoS ONE (2012)

Forest plot evaluating the relationship between insulin glargine and breast cancer incidence.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3526637&req=5

pone-0051814-g003: Forest plot evaluating the relationship between insulin glargine and breast cancer incidence.
Mentions: Eight studies [7], [23], [24], [26]–[29], [31] including 284, 402 study subjects and 1, 364 breast cancer patients reported the of breast cancer in insulin glargine users. The overall OR for the eight studies was 0.99 (95% CI 0.68 to 1.46, P = 0.966; very low-quality evidence) in a random-effects model for insulin glargine versus non-glargine insulin. A significant heterogeneity was detected (P = 0.000, I2 = 79.9%, Table 2 and Figure 3). In stratified analyses by study design [7], [23], [24], [26]–[29], the odds of breast cancer was not elevated with insulin glargine use compared to non-glargine insulin use in observational studies (OR 1.02, 95% CI 0.68 to 1.53, P = 0.92; p for heterogeneity = 0.000, I2 = 83%). After removing two studies by Morden et al.[27], and Colhoun et al.[7] in which not all patients were free of a history of any cancer before cohort entry, the overall outcome remained the same (OR 0.77, 95% CI 0.49 to 1.21, P = 0.26), with significant heterogeneity (P = 0.002, I2 = 73%).

Bottom Line: Insulin glargine use was associated with a lower odds of cancer compared with non-glargine insulin use (OR 0.81, 95% CI 0.68 to 0.98, P = 0.03; very low-quality evidence).Glargine did not increase the odds of breast cancer (OR 0.99, 95% CI 0.68 to 1.46, P = 0.966; very low-quality evidence).Compared with non-glargine insulin, no significant association was found between insulin glargine and prostate cancer, pancreatic cancer and respiratory tract cancer.

View Article: PubMed Central - PubMed

Affiliation: Department of Endocrinology, the First Hospital of Lanzhou University, Lanzhou, Gansu, China. xulei_tang@126.com

ABSTRACT

Aim: The role of insulin glargine as a risk factor for cancer is controversial in human studies. The aim of this meta-analysis was to evaluate the relationship between insulin glargine and cancer incidence.

Methods: All observational studies and randomized controlled trials evaluating the relationship of insulin glargine and cancer risk were identified in PubMed, Embase, Web of Science, Cochrane Library and the Chinese Biomedical Medical Literature Database, through March 2012. Odds ratios (ORs) with corresponding 95% confidence interval (CI) were calculated with a random-effects model. Confidence in the estimates of the obtained effects (quality of evidence) was assessed by using the Grading of Recommendations Assessment, Development, and Evaluation approach.

Results: A total of 11 studies including 448,928 study subjects and 19,128 cancer patients were finally identified for the meta-analysis. Insulin glargine use was associated with a lower odds of cancer compared with non-glargine insulin use (OR 0.81, 95% CI 0.68 to 0.98, P = 0.03; very low-quality evidence). Glargine did not increase the odds of breast cancer (OR 0.99, 95% CI 0.68 to 1.46, P = 0.966; very low-quality evidence). Compared with non-glargine insulin, no significant association was found between insulin glargine and prostate cancer, pancreatic cancer and respiratory tract cancer. Insulin glargine use was associated with lower odds of other site-specific cancer.

Conclusions: Results from the meta-analysis don't support the link between insulin glargine and an increased risk of cancer and the confidence in the estimates of the effects is very low. Further studies are needed to examine the relation between insulin glargine and cancer risk, especially breast cancer.

Show MeSH
Related in: MedlinePlus